Jubilant Pharmova Q2FY26: Revenue Rises 12 Per Cent YoY, PAT Up 21 Per Cent

3 weeks ago —by Salil Urunkar

Jubilant Pharmova Q2FY26 results show 12% revenue growth and 21% PAT rise, driven by strong CDMO, Radiopharma, and Allergy Immunotherapy performance.

Jubilant Pharmova Q2FY26 Revenue